ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. See why SPRY stock is a Buy.
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback